Status:
RECRUITING
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
Lead Sponsor:
New York Medical College
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Janssen Pharmaceuticals
Conditions:
Pulmonary Vascular Disease
Pulmonary Arterial Hypertension
Eligibility:
All Genders
1-21 years
Brief Summary
Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their under...
Detailed Description
Pulmonary Hypertension (PH) is a syndrome characterized by vasoconstriction and abnormal growth and function of endothelial and smooth muscle cells and other components within the pulmonary vessels, w...
Eligibility Criteria
Inclusion
- The subject's age of onset of pulmonary hypertension must be prior to age 18 years
- The person providing consent must be able to read either Spanish or English.
- The subject (and/or parent/legal guardian) must be able to provide informed consent
Exclusion
- Diagnosed with pulmonary hypertension after age 18
- Refusal to sign informed consent
Key Trial Info
Start Date :
October 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2031
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT02249923
Start Date
October 1 2014
End Date
December 1 2031
Last Update
March 13 2025
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University Medical Center
Palo Alto, California, United States
2
University California San Francisco
San Francisco, California, United States
3
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
4
Johns Hopkins All Children's Heart Institute
St. Petersburg, Florida, United States